Company intelligence / Profile preview

AUM LifeTech

Philadelphia, Pennsylvania, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Preclinical stage biotech developing FANA ASO RNA silencing technology for gene therapy in genetically defined diseases and cancer immunotherapy, with a $400,000 NCI/NIH SBIR grant awarded in 2022 for lung cancer program targeting FOXP3 mRNA to inhibit Tregs.

Therapeutic areas: Oncology
Modalities: Antisense oligonucleotide
Industry: Biotech

Beyond the preview

Go deeper on AUM LifeTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUM LifeTech.

Explore the full profile